IL273909B1 - Treatment of CD20-positive B-cell lymphoma with obinutuzumab - Google Patents

Treatment of CD20-positive B-cell lymphoma with obinutuzumab

Info

Publication number
IL273909B1
IL273909B1 IL273909A IL27390920A IL273909B1 IL 273909 B1 IL273909 B1 IL 273909B1 IL 273909 A IL273909 A IL 273909A IL 27390920 A IL27390920 A IL 27390920A IL 273909 B1 IL273909 B1 IL 273909B1
Authority
IL
Israel
Prior art keywords
obinutuzumab
hour
cycle
administration
pharmaceutical composition
Prior art date
Application number
IL273909A
Other languages
Hebrew (he)
Other versions
IL273909A (en
IL273909B2 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL273909(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL273909A publication Critical patent/IL273909A/en
Publication of IL273909B1 publication Critical patent/IL273909B1/en
Publication of IL273909B2 publication Critical patent/IL273909B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)

Claims (14)

1. 273909/ CLAIMS[Claim 1] A pharmaceutical composition for treating CD20-positive B-cell lymphoma comprising obinutuzumab, which is intravenously drip infused at 1000 mg of obinutuzumab per administration, and given according to the administration speeds of the following (a) and (b) in two or more cycles: (a) the maximum administration speed in the first cycle is equal to or more than 200 mg of obinutuzumab an hour, preferably equal to or more than 300 mg of obinutuzumab an hour, more preferably equal to or more than 400 mg of obinutuzumab an hour; (b) the maximum administration speed in the second or later cycle is equal to or more than 800 mg of obinutuzumab an hour, preferably equal to or more than 900 mg of obinutuzumab an hour.
2. [Claim 2] The pharmaceutical composition according to claim 1, wherein a duration per administration in the second or later cycle is within 180 minutes, preferably within 1minutes, more preferably within 120 minutes, the most preferably within 90 minutes.
3. [Claim 3] The pharmaceutical composition according to claim 1 or 2, which is administered times in the first cycle, and once a cycle in the second or later cycle.
4. [Claim 4] The pharmaceutical composition according to claim 3, wherein the first administration in the first cycle is initiated at a speed of 50 mg of obinutuzumab an hour, and the second or later administration in the first cycle is initiated at a speed of 100 mg of obinutuzumab an hour.
5. [Claim 5] The pharmaceutical composition according to any one of claims 1 to 4, wherein the administration speed in the second or later cycle is increased to 700 mg of obinutuzumab an hour or faster, preferably to 800 mg of obinutuzumab an hour or faster, more preferably up to 900 mg of obinutuzumab an hour.
6. [Claim 6] The pharmaceutical composition according to any one of claims 1 to 5, wherein, in (b), the pharmaceutical composition is given according to at least one of the following (c) to (e) conditions: (c) if no infusion reaction of Grade 3 or above appeared with the last three administrations, and the number of lymphocytes in peripheral blood before administration is less than 5000/μL, administration is carried out at 100 mg/hour for 30 273909/ minutes. If no infusion reaction is observed all that time, the speed can be increased to 900 mg/hour. Depending on the condition of the patient, the speed is decreased to, for example, the administration speed in cycle 1, as appropriate. (d) if an infusion reaction of Grade 1/2 appeared, administration is restarted at half the speed before administration was stopped. If no infusion reaction is observed in minutes, the speed can be increased to 900 mg/hour. (e) if an infusion reaction of Grade 3, administration is restarted at 200 mg/hour or lower. If no infusion reaction is observed in 30 minutes, the speed can be increased by mg/hour every 30 minutes to a maximum of 400 mg/hour.
7. [Claim 7] The pharmaceutical composition according to any one of claims 1 to 6, which is administered on days 1, 8 and 15 in the first cycle, and on day 1 in the second or later cycle.
8. [Claim 8] The pharmaceutical composition according to any one of claims 1 to 7, wherein each cycle is 3 weeks.
9. [Claim 9] The pharmaceutical composition according to any one of claims 1 to 7, which is used in combination with at least one of other anti-tumor agents, and whose administration cycle is synchronized with a dosing cycle of said at least one of other anti-tumor agents, wherein the dosing cycle is 4 weeks a cycle.
10. [Claim 10] The pharmaceutical composition according to claim 9, wherein said at least one of other anti-tumor agents is selected from CHOP, CVP, bendamustine, fludarabine, lenalidomide, an anti-PD-1 antibody, and an anti-PD-L1 antibody.
11. [Claim 11] The pharmaceutical composition according to any one of claims 1 to 10, wherein the pharmaceutical composition is given every two months for two years as maintenance monotherapy after said two or more cycles.
12. [Claim 12] The pharmaceutical composition according to any one of claims 1 to 11, wherein the obinutuzumab concentration in infusion fluid when intravenously drip infused is 10 to mg/mL, preferably 20 to 30 mg/mL, more preferably 25 mg/mL.
13. [Claim 13] The pharmaceutical composition according to any one of claims 1 to 12, further comprising a trehalose hydrate, L-histidine, L-histidine hydrochloride hydrate, or 273909/ polyoxyethylene (160) polyoxypropylene (30) glycol as an additive.
14. [Claim 14] Obinutuzumab for use in a manufacture of a pharmaceutical composition for treating CD20-positive B-cell lymphoma comprising obinutuzumab, wherein the composition is intravenously drip infused at 1000 mg of obinutuzumab per administration, and given according to the administration speeds of the following (a) and (b) in two or more cycles: (a) the maximum administration speed in the first cycle is equal to or more than 200 mg of obinutuzumab an hour, preferably equal to or more than 300 mg of obinutuzumab an hour, more preferably equal to or more than 400 mg of obinutuzumab an hour; (b) the maximum administration speed in the second or later cycle is equal to or more than 800 mg of obinutuzumab an hour, preferably equal to or more than 900 mg of obinutuzumab an hour.
IL273909A 2017-10-19 2018-10-19 Treatment of CD20-positive B-cell lymphoma with obinutuzumab IL273909B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 A pharmaceutical composition

Publications (3)

Publication Number Publication Date
IL273909A IL273909A (en) 2020-05-31
IL273909B1 true IL273909B1 (en) 2025-08-01
IL273909B2 IL273909B2 (en) 2025-12-01

Family

ID=64362606

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273909A IL273909B2 (en) 2017-10-19 2018-10-19 Treatment of CD20-positive B-cell lymphoma with obinutuzumab
IL321935A IL321935A (en) 2017-10-19 2018-10-19 Treatment of cd20-positive b-cell lymphoma with obituzumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL321935A IL321935A (en) 2017-10-19 2018-10-19 Treatment of cd20-positive b-cell lymphoma with obituzumab

Country Status (14)

Country Link
US (2) US12129304B2 (en)
EP (2) EP3697818B1 (en)
JP (2) JP6860652B2 (en)
KR (3) KR20260011191A (en)
CN (2) CN111212854A (en)
AU (2) AU2018303836B2 (en)
BR (1) BR112020007731A2 (en)
CA (1) CA3079374A1 (en)
ES (1) ES3005784T3 (en)
IL (2) IL273909B2 (en)
MX (2) MX419643B (en)
PL (1) PL3697818T3 (en)
TW (2) TWI828593B (en)
WO (1) WO2019017499A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3697818T3 (en) * 2017-10-19 2025-03-24 F. Hoffmann-La Roche Ag Treatment of CD20-positive B-cell lymphoma with obinutuzumab
AU2020356896B2 (en) * 2019-10-04 2026-07-30 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant CD20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type II anti-CD20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
WO2023042679A1 (en) 2021-09-17 2023-03-23 キヤノン株式会社 Power transmission device and power reception device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024228A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038955T2 (en) 2003-11-05 2018-12-28 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2009080541A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Antibody formulation
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (en) * 2017-02-08 2021-02-05 西比曼生物科技(香港)有限公司 Construction of targeting CD20 antigen chimeric antigen receptor and activity identification of engineered T cell thereof
US12377681B2 (en) 2017-07-21 2025-08-05 The Yokohama Rubber Co., Ltd. Pneumatic tire
PL3697818T3 (en) * 2017-10-19 2025-03-24 F. Hoffmann-La Roche Ag Treatment of CD20-positive B-cell lymphoma with obinutuzumab

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024228A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUILLAUME CARTRON ET AL,, OBINUTUZUMAB (GA101) IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: FINAL DATA FROM THE PHASE 1/2 GAUGUIN STUDY, 20 August 2014 (2014-08-20) *
TOBINAI KENSEI ET AL,, A REVIEW OF OBINUTUZUMAB (GA101), A NOVEL TYPE II ANTI-CD20 MONOCLONAL ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH B-CELL MALIGNANCIES, 21 December 2016 (2016-12-21) *
TSUJIMURA HIDEKI,, SAFETY AND TOLERABILITY OF OBINUTUZUMAB (GA101) WITH SHORTER DURATION OF INFUSION IN JAPANESE PATIENTS WITH PREVIOUSLY UNTREATED CD20-POSITIVE B-CELL NON-HODGKIN'S LYMPHOMA (NHL)-COMPARISON WITH GAO4915G (GATHER) AND BO21005 (GOYA) STUDIES | BLOOD JO, 2 December 2016 (2016-12-02) *

Also Published As

Publication number Publication date
WO2019017499A2 (en) 2019-01-24
MX2020003418A (en) 2020-07-20
CN120983618A (en) 2025-11-21
TWI828593B (en) 2024-01-01
TW202342099A (en) 2023-11-01
JP2019528282A (en) 2019-10-10
JP6860652B2 (en) 2021-04-21
IL321935A (en) 2025-09-01
KR20200067196A (en) 2020-06-11
TW201922284A (en) 2019-06-16
JP2021152002A (en) 2021-09-30
EP3697818B1 (en) 2024-11-27
CA3079374A1 (en) 2019-01-24
KR20240157135A (en) 2024-10-31
BR112020007731A2 (en) 2020-10-20
IL273909A (en) 2020-05-31
WO2019017499A3 (en) 2019-02-21
EP4520347A3 (en) 2025-06-04
EP4520347A2 (en) 2025-03-12
US20250026847A1 (en) 2025-01-23
MX419643B (en) 2025-01-14
KR20260011191A (en) 2026-01-22
IL273909B2 (en) 2025-12-01
US12129304B2 (en) 2024-10-29
MX2024009217A (en) 2024-11-08
KR102766089B1 (en) 2025-02-13
JP7370357B2 (en) 2023-10-27
TWI805630B (en) 2023-06-21
AU2025205481A1 (en) 2025-08-07
KR102906969B1 (en) 2026-01-05
PL3697818T3 (en) 2025-03-24
AU2018303836B2 (en) 2025-04-17
US20200299398A1 (en) 2020-09-24
ES3005784T3 (en) 2025-03-17
CN111212854A (en) 2020-05-29
AU2018303836A1 (en) 2020-05-14
EP3697818A2 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
HRP20230504T1 (en) Activin-actrii antagonists and uses for treating myelodysplastic syndrome
IL263110B (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
JP2017510579A5 (en)
Keller et al. Clinical pharmacodynamics: principles of drug response and alterations in kidney disease
US20200308297A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
JP2010515709A5 (en)
JP2018522850A5 (en)
JP7491220B2 (en) Cancer treatment in combination with immune checkpoint inhibitors and FOLFIRINOX therapy
JP2011511072A5 (en)
US20200308284A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone
HRP20240904T1 (en) Mirikizumab in the treatment of ulcerative colitis
US20200316197A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
HRP20201632T4 (en) Melflufen dosage regimens for cancer
US20210369746A1 (en) Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
IL321935A (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
JP2023539625A5 (en)
JP2021152002A5 (en)
JP2022501332A5 (en)
JP2017527551A5 (en)
RU2020111574A (en) HIGHLY CONCENTRATED, LOW-VISCOUS PREPARATIONS OF INHIBITING MASP-2 ANTIBODIES, KITS AND METHODS FOR TREATMENT OF SUBJECTS SUFFERING WITH ATYPICAL HEMOLYTIC SYNDROME
KR20240107337A (en) Complex drugs for use in cancer treatment
Wolf et al. Peripheral administration of antithymocyte globulins: a review of current literature
HK40125832A (en) Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
Vial Respiratory Syncytial Virus (RSV)
RU2024111538A (en) COMBINED THERAPY OF MALIGNANT NEOPOLOGY USING A BIPHENYL COMPOUND AND A REGULATOR OF IMMUNE CHECKPOINT MOLECULES